Tvardi Therapeutics, Inc. (TVRD) stock
TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.99+0.04 (+4.57%)
Close on Nov 20, 2026Market cap $13.20MP/E –Yield 0.00%
Tvardi Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Tvardi Therapeutics's free cash flow for the twelve months ending Dec 31, 2024 was -$19.35M. For fiscal 2024 it was -$19.35M. The highest annual figure on record is $2.82M in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$19.35M | – |
| FY2023 | Dec 31, 2023 | -$94.45M | – |
| FY2022 | Dec 31, 2022 | -$78.77M | – |
| FY2021 | Dec 31, 2021 | -$60.13M | – |
| FY2020 | Dec 31, 2020 | -$5.84M | – |
| FY2019 | Dec 31, 2019 | -$109.24M | – |
| FY2018 | Dec 31, 2018 | -$22.37M | – |
| FY2017 | Dec 31, 2017 | -$54.89M | – |
| FY2016 | Dec 31, 2016 | -$48.10M | – |
| FY2015 | Dec 31, 2015 | -$21.50M | – |
| FY2014 | Dec 31, 2014 | -$17.68M | -726.2% |
| FY2013 | Dec 31, 2013 | $2.82M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$4.83M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.66M | – |
| Q2 FY2024 | Jun 30, 2024 | $23.43M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.29M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.51M | -128.7% |
| Q3 FY2022 | Sep 30, 2022 | -$25.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.50M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.57M | – |
| Q4 FY2020 | Dec 31, 2020 | $81.92M | – |
| Q4 FY2019 | Dec 31, 2019 | -$31.17M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.64M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.90M | -160.7% |
| Q1 FY2019 | Mar 31, 2019 | -$27.54M | – |
| Q4 FY2018 | Dec 31, 2018 | -$24.39M | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.52M | – |
| Q2 FY2018 | Jun 30, 2018 | $41.00M | – |
| Q1 FY2018 | Mar 31, 2018 | -$18.47M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.41M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.88M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.95M | – |
| Q1 FY2017 | Mar 31, 2017 | -$21.64M | – |
| Q4 FY2016 | Dec 31, 2016 | -$13.26M | – |
| Q3 FY2016 | Sep 30, 2016 | -$13.39M | – |
See a number that looks wrong?